Sanofi said gastrointestinal concerns have made its experimental GLP-1 phase 2 drug SAR425899 “not acceptable for clinical use,” but it is undertaking new tests to try to get around dosing issues, which it blames for the AEs.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,